Calcium Replacement in Massive Transfusion

Massive Transfusion: VitaCal Calcium Replacement

Purpose

• Prevent or treat transfusion-associated hypocalcemia during massive hemorrhage resuscitation.
• Citrate in transfused blood products binds ionized calcium. Monitor and correct ionized calcium during ongoing bleeding and transfusion.

Proposed Local VitaCal Rule

• VitaCal concentration: 400 mg per ampule.
• After 4 units of PRBCs: give 2.5 ampules of VitaCal.
  • Calculation: 2.5 × 400 mg = 1,000 mg = 1 g calcium gluconate.
• After 8 units of PRBCs: give 5 ampules of VitaCal.
  • Calculation: 5 × 400 mg = 2,000 mg = 2 g calcium gluconate.
• Reassess ionized calcium, ECG, hemodynamics, and the ongoing transfusion rate. Do not use a fixed schedule as a substitute for clinical monitoring.

Evidence Base

• Rajesh et al. performed a retrospective, single-center Level III cohort study of trauma patients receiving low-titer O whole blood (LTOWB) and calcium prehospital or within 4 hours of arrival.
• In adjusted analysis, at least 1 g calcium chloride per 2 units of LTOWB was associated with lower odds of 24-hour mortality.
• The study found no significant association for calcium gluconate in the subgroup with greater LTOWB requirements.
• The authors concluded that prospective validation is needed.

Important Interpretation Limit

• The published threshold is calcium chloride per LTOWB, not calcium gluconate per PRBC.
• 1 g calcium gluconate is not pharmacologically equivalent to 1 g calcium chloride. Calcium chloride provides more elemental calcium per gram.
• Therefore, the proposed “2.5 VitaCal ampules after 4U PRBC” rule is a local operational adaptation, not a direct dose conversion from the cited study.
• Confirm the institutional massive transfusion protocol, the exact VitaCal formulation, line-access requirements, and ionized-calcium targets before adopting it as a standing order.

Practical Bedside Checklist

• Activate hemorrhage control and balanced resuscitation in parallel.
• Send or obtain serial ionized calcium when available.
• Give calcium using appropriate IV access and cardiac monitoring according to local medication policy.
• Watch for severe hypocalcemia, including hypotension, reduced myocardial contractility, prolonged QT interval, or arrhythmia.
• Reassess after each transfusion cycle and adjust to ionized calcium and clinical status.

Summary Takeaway

• Proposed local rule: VitaCal 400 mg/ampule, 2.5 ampules after 4U PRBCs and 5 ampules after 8U PRBCs.
• Evidence-supported threshold studied: at least 1 g calcium chloride per 2U LTOWB in a retrospective trauma cohort.
• Do not claim direct equivalence between the VitaCal PRBC rule and the calcium-chloride LTOWB study threshold.

Reference

Rajesh A, Barry L, Limon D, et al. Aggressive calcium chloride dosing reduces early mortality in trauma patients receiving whole blood resuscitation. Journal of Trauma and Acute Care Surgery. 2026;101(1):57-64. doi: 10.1097/TA.0000000000005009

---

Evidence scope: retrospective single-center trauma cohort using LTOWB.

Neuroleptic Malignant Syndrome

Neuroleptic Malignant Syndrome: Lecture Notes

Definition and Clinical Significance

• Neuroleptic malignant syndrome (NMS) is a life-threatening syndrome associated with dopamine antagonism or abrupt withdrawal of dopaminergic therapy.
• Suspect NMS when relevant medication exposure is followed by:
  • Fever
  • Generalized lead-pipe rigidity
  • Altered mental status
  • Autonomic instability

Triggers and Risk Factors

• Relevant triggers include:
  • Antipsychotics
  • Metoclopramide
  • Prochlorperazine
  • Promethazine
  • Abrupt withdrawal of dopaminergic therapy
• Factors that increase risk include:
  • Rapid dose escalation
  • Dehydration
  • Agitation requiring intramuscular injections
  • Neurologic disease

Diagnosis and Differential Diagnosis

• NMS is a clinical diagnosis. No laboratory test confirms it.
• Levenson criteria use fever and rigidity plus at least 2 additional features:
  • Altered mental status
  • Tachycardia
  • Tachypnea
  • Leukocytosis
  • Elevated creatine kinase (CK)
• Obtain a medication history while evaluating competing immediately life-threatening diagnoses.
• Key differential diagnoses:
  • Serotonin syndrome: commonly develops within minutes to hours after exposure and features hyperreflexia and spontaneous or inducible clonus.
  • NMS: commonly evolves over days to weeks, with reduced reflexes and no clonus.
  • Malignant hyperthermia: follows anesthetic exposure.

Evaluation and Monitoring

• Obtain and monitor:
  • CK
  • Renal function
  • Urine output
  • Electrolytes
  • Acid-base status
  • Electrocardiogram (ECG)
• Rhabdomyolysis may cause myoglobinuria, acute kidney injury, hyperkalemia, hyperphosphatemia, hypocalcemia, and arrhythmias.
• A urine dipstick positive for blood without red blood cells may indicate myoglobin, not hematuria alone.

Immediate Management

• Stop all antipsychotics and other dopamine antagonists immediately.
• Begin supportive care in parallel:
  • Intravenous hydration
  • Active cooling
  • Cardiorespiratory monitoring
  • Serial temperature, CK, renal function, electrolytes, and urine-output assessment
• Benzodiazepines are listed as first-line medication for agitation and muscle relaxation.

Escalation and Disposition

• If response is inadequate, the local source lists dantrolene or bromocriptine as escalation options.
• Amantadine or dopamine replacement are listed as adjunctive choices.
• Severe rigidity with respiratory compromise may require intubation and neuromuscular paralysis.
• Refractory cases may require electroconvulsive therapy.
• Suspected NMS warrants hospital admission, typically intensive care.

Clinical Pitfalls and Takeaway

• Avoid delayed recognition.
• Do not treat fever without removing the trigger.
• Avoid anchoring on infection before considering NMS.
• Medication choices and doses require review against current institutional toxicology, pharmacy, and critical-care protocols.

---

This educational summary does not establish medication dosing or replace institutional protocols.